

- **Full Name:** Hyung-Don Kim

- **Current Position & Affiliation:** Assistant professor & Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine

- **Country:** South Korea

- **Educational Background:**

B.S. Chung-Ang University College of Medicine, Seoul, Korea, 2005-2011

M.S. University of Ulsan College of Medicine, Seoul, Korea, 2014-2016

Ph.D. Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea, 2016-2020

- **Professional Experience:**

Internship, Asan Medical Center, Seoul, Korea, 2011-2012

Residency, Department of Internal Medicine, Asan Medical Center, Seoul, Korea, 2012-2016

Clinical fellowship, Department of Oncology, Asan Medical Center, Seoul, Korea, 2020-2021

Clinical instructor, Department of Oncology, Asan Medical Center, Seoul, Korea, 2021-2022

Assistant professor, Department of Oncology, Asan Medical Center, Seoul, Korea, 2022-

- **Professional Organizations:**

Korean Society of Medical Oncology

Korean Cancer Study Group

The Korean Liver Cancer Study Group

European Society for Medical Oncology

American Society of Clinical Oncology

- **Main Scientific Publications:**

Association Between Expression Level of PD1 by Tumor-Infiltrating CD8⁺ T Cells and Features of Hepatocellular Carcinoma.

Gastroenterology. 2018 Dec;155(6):1936-1950.

4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8⁺ T cells in Hepatocellular Carcinoma.

Hepatology. 2020 Mar;71(3):955-971.

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

J Immunother Cancer. 2021 Jul;9(7):e002428.

Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: An exploratory analysis from the PRODIGY study.

Gastric Cancer. 2022 Jan;25(1):170-179.

Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.

Gastric Cancer. 2022 Aug 3. doi: 10.1007/s10120-022-01325-6.

A randomized phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors.

Br J Cancer. 2023